<DOC>
	<DOC>NCT00035321</DOC>
	<brief_summary>The purposes of this study are to determine: - Whether olanzapine plus fluoxetine in combination will help patients with treatment-resistant major depression. - The safety of olanzapine plus fluoxetine in combination, plus and any side effects that might be associated with the combination. - The effectiveness of olanzapine plus fluoxetine compared to olanzapine and fluoxetine alone.</brief_summary>
	<brief_title>The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Male or female patients, 18 65 years of age. Each patient must have a level of understanding sufficient to perform all tests and examinations required by the protocol, and must be considered reliable according to the investigator's clinical judgement Patients must fulfill the criteria for recurrent MDD without psychotic features as defined by the DSMIV, based on clinical assessment and confirmed by Structured Clinical Interview for DSMIV Axis I Disorders Clinical Version (SCIDI) plus the Major Depressive Disorder Specifiers included in the Research Version of the SCIDI. This includes at least one of the following diagnoses: 296.31, 296.32, and 296.33 Female patients of childbearing potential must be using a medically accepted means of contraception throughout the course of the study. Use of any oral or injectable contraception must be initiated prior to visit 2 Failure to achieve satisfactory antidepressant response to an adequate trial of an antidepressant (except fluoxetine), for at least 6 weeks at an acceptable dose or greater, occurring within the current episode of MDD Treatment with a drug within the last 30 days that has not received regulatory approval at the time of study entry Exposure to OFC in a Lillysponsored clinical trial investigating OFC, and any patients historically failing to respond to olanzapine and fluoxetine in combination under any circumstance Persons who have previously entered any Lillysponsored study which was investigating olanzapine Female patients who are either pregnant or nursing Serious, unstable illnesses for which death is anticipated within 1 year of intensive care unit hospitalization for the disease is anticipated within 6 months. This includes hepatic (specifically any degree of jaundice), renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic diseases (specifically current agranulocytosis with an absolute neutrophil count &lt; 500 mm_3)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2006</verification_date>
</DOC>